- Home
- OR vs PRAX Comparison
OR vs PRAX Comparison
Compare OR & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OR | PRAX |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 7.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | OR | PRAX |
|---|---|---|
| Price | $40.29 | $300.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $36.25 | ★ $397.85 |
| AVG Volume (30 Days) | ★ 1.4M | 569.5K |
| Earning Date | 02-18-2026 | 02-27-2026 |
| Dividend Yield | ★ 0.52% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.78 | N/A |
| Revenue | ★ $243,647,000.00 | $7,463,000.00 |
| Revenue This Year | $89.31 | N/A |
| Revenue Next Year | $31.35 | $14,827.76 |
| P/E Ratio | $52.23 | ★ N/A |
| Revenue Growth | 33.28 | ★ 364.98 |
| 52 Week Low | $17.55 | $26.70 |
| 52 Week High | $42.25 | $317.72 |
Technical Indicators
Market Signals| Indicator | OR | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 68.20 | 62.93 |
| Support Level | $35.45 | $266.93 |
| Resistance Level | $41.44 | $306.16 |
| Average True Range (ATR) | 1.30 | 16.00 |
| MACD | 0.39 | -2.53 |
| Stochastic Oscillator | 86.08 | 66.07 |
Price Performance
Historical ComparisonAbout OR Osisko Gold Royalties Ltd
OR Royalties Inc, formerly Osisko Gold Royalties Ltd is engaged in the business of acquiring and managing precious metal and other high-quality royalties, streams and similar interests. The Company owns a portfolio of royalties, streams, offtakes, options on royalty/stream financings and exclusive rights to participate in future royalty/stream financings on various projects. Geographically, it generates majority of its income from North America and also generates some portions of income from South America, Australia, Africa and Europe.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.